Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 75.48

+1.4%

Nov 14 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2767)	4/15/2010 9:50:23 AM
From: Jibacoa	Read Replies (1) of 3722

ANDS is up 15.33% as it is facing the resistance from the $3 level and the H of Dec16 at $3.02 <g> It opened with a good UG and volume above 1.82M is >3x its ADV bigcharts.marketwatch.com It announced today that 72% of hepatitis C patients receiving ANA598 400 mg B.I.D., plus standard of care, achieved undetectable levels of virus at eight weeks in an ongoing PII, compared to 38% of patients receiving placebo. The preliminary analysis of results through eight weeks also showed that ANA598 400 mg bid plus SOC was well tolerated, with an adverse event profile comparable to SOC alone. As seen before at 200 mg B.I.D, no patient experienced viral breakthrough on ANA598. <g> The ACTAY is $5 and it seems thyat with some good news it could get to the $4 level.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next